MHRA alert: Benzodiazepines and opioids - reminder of risk of potentially fatal respiratory depression (March 2020) (www.gov.uk).

DIAZEPAM

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 2mg, 5mg, 10mg

Important: Formulation and dosage details

Formulation:

Oral solution 2mg/5mL

Important: Formulation and dosage details

Formulation:

Rectal solution 5mg/2·5mL, 10mg/2·5mL

LORAZEPAM

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 1mg

Important: Formulation and dosage details

Formulation:

Solution for injection 4mg/mL (licensed and unlicensed preparations)

MIDAZOLAM

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Oromucosal solution 50mg/5mL (Epistatus®) (CD schedule 3) unlicensed

Important: Formulation and dosage details

Formulation:

Solution for injection 10mg/2mL, 5mg/5mL (CD schedule 3)

Dosage:

The 10mg/2mL injection is used in Palliative Care as a subcutaneous bolus injection; refer to Scottish Palliative Care Guidelines.

Important: Formulation and dosage details

Formulation:

Solution for infusion 50mg/50mL (CD schedule 3)

MIDAZOLAM WITH LIDOCAINE

Important: Formulation and dosage details

Formulation:

Nasal solution (midazolam 20mg, lidocaine 10mg/0·5mL (CD schedule 3) unlicensed

Dosage:

For use by anaesthetists only, for the sedation of patients for whom traditional methods of sedation (oral or intravenous) are contraindicated or unsuitable.

TEMAZEPAM

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 10mg

Important: Formulation and dosage details

Formulation:

Oral solution 10mg/5mL

Editorial Information

Document Id: F015